THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, April 27, 2022
CinCor Pharma has raised $143 million for the development of treatment for severe hypertension and its resulting diseases.
Fremont, CA:Hypertension is a long-term condition that can be managed with medicines but not cured. As a result, patients must adhere to their doctor's recommendations for therapy and lifestyle changes. Hypertension, if left untreated, can lead to severe conditions like heart attack, stroke, heart or kidney failure, and blindness. CinCor Pharma has raised $143 million in a Series B round of funding. CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase in development for the treatment of hypertension, primary aldosteronism, and chronic renal disease, will benefit from the funds from this round. The new funding will allow the ongoing brigHTN Phase 2 clinical trial in patients with resistant hypertension and the ongoing Phase 2 Spark trial in hypertensive individuals with primary aldosteronism to be completed, as well as the start of two new trials: a Phase 2 clinical trial (HALO) in patients with uncontrolled hypertension and a study of CIN-107's impact on blood pressure.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
“This financing will enable us to obtain the data that we hope will establish that aldosterone synthesis inhibition is a potent approach to lowering blood pressure in several patient groups, including individuals with hypertension demonstrated to be resistant to existing treatment options,” said Marc de Garidel, Chief Executive Officer of CinCor. “In addition, it will enable us to continue to obtain data that may expand the potential utility of CIN-107 into other indications including primary aldosteronism and CKD. We welcome our new high-quality investors to CinCor and Jason to the Board.”
“There has been little innovation in the treatment of hypertension in the past several decades, along with a lack of incorporating targeted approaches seen in other fields. Currently, a large portion of hypertensive patients still do not reach treatment goals, increasing their risk of heart attack and stroke alongside more slowly developing conditions. By using a precision approach to target indications and patient populations where aldosterone is likely a primary driver of disease, CIN-107 has the potential to be a significant innovation for patients with difficult-to-treat cardiovascular conditions. We look forward to working with the company as they continue to advance in the clinic,” said Jason Pitts, Ph.D., Vice President at General Atlantic.
More in News